. . . . . "Samir Naik, Anthony Crasto, Narendra Joshi, Sachin Srivastava, \"Amorphous frovatriptan succinate and process for the preparation thereof.\" U.S. Patent US20070299123, issued December 27, 2007."@en . . . . "Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT_1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT_1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT_1B receptor agonism."@en . . . "* 4.2 L/kg [males] * 3 L/kg [females]"@en . . . . . . . "158747-02-5"@en . . . "Frovatriptan succinate"@en . . . . . "26 hours"@en . . "approved"@en . . . . . . . " "@en . "investigational"@en . . "Binding to serum proteins is low (approximately 15%). Reversible binding to blood cells at equilibrium is approximately 60%."@en . . . . . "There is no direct experience of any patient taking an overdose of Frovatriptan. The maximum single dose of frovatriptan given to male and female patients with migraine was 40 mg (16 times the clinical dose) and the maximum single dose given to healthy male subjects was 100 mg (40 times the clinical dose) without significant adverse events."@en . . . . . "Allergo filmtabletten"@en . "For the acute treatment of migraine attacks with or without aura in adults."@en . . "Take without regard to meals."@en . "Food does not affect amount of absorption but delays maximal levels by about 1 hour."@en . . . . . . . "Radiolabeled compounds excreted in urine were unchanged frovatriptan, hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, together with several other minor metabolites. Less than 10% of frovatriptan was excreted in urine after an oral dose."@en . . . . "Frovatriptan"@en . . . "Frovatriptan (Frova\u00AE) is a triptan drug developed by Vernalis for the treatment of migraine headaches, in particular those associated with menstruation. The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[1] Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets. Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than other triptans. Frovatriptan is available only by prescription in the United States, where a secondary New Drug Approval (sNDA) was filed in July 2006[2] and which is currently pending.[3] The FDA anticipates completing its review of this application on or before the current PDUFA (Prescription Drug User Fee Act) review date of August 19, 2007. If the sNDA is approved, Frova\u00AE will be the only medication indicated in the U.S. for the short-term prevention of menstrual migraine (MM)."@en . "Frovatriptan is rapidly absorbed from the duodenum, but has low oral bioavailability."@en . . . . "# Markus F, Mikko K: Frovatriptan review. Expert Opin Pharmacother. 2007 Dec;8(17):3029-33. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18001261 # Easthope SE, Goa KL: Frovatriptan. CNS Drugs. 2001;15(12):969-76; discussion 977-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11735616 # Balbisi EA: Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine. Ther Clin Risk Manag. 2006 Sep;2(3):303-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18360605 # Balbisi EA: Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine. Int J Clin Pract. 2004 Jul;58(7):695-705. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15311727 # Elkind AH, Wade A, Ishkanian G: Pharmacokinetics of frovatriptan in adolescent migraineurs. J Clin Pharmacol. 2004 Oct;44(10):1158-65. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15342617 # Jhee SS, Shiovitz T, Crawford AW, Cutler NR: Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet. 2001;40(3):189-205. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11327198"@en . "Humans and other mammals"@en . . . . . . . "* 220 mL/min [male receiving IV dose of 0.8 mg] * 130 mL/min [Female receiving IV dose of 0.8 mg]"@en .